Video

March 31, 2022

Lupus Treatment Advances: Agents in the Pipeline

Novel therapies in the pipeline that demonstrate potential advantages when used as treatment for systemic lupus erythematosus and lupus nephritis.

Related Videos

John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research

Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis

Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool

Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis

$Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome$

Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine

John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates

Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s

Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis

Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.